

January 09, 2020

The Secretary,
Listing Department,
BSE Limited,
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai
400 001

Scrip Code: 540975

The Manager,
Listing Department,
The National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex,
Bandra (East), Mumbai,
400 051

Scrip Code: ASTERDM

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on January 09, 2020 pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Meeting of the Board of Directors commenced at 12.00 noon (IST) and concluded at 2.15 pm (IST).

We refer to our intimation dated January 06, 2020.

We wish to inform you that the Board of Directors of Aster DM Healthcare Limited (the "Company") at its meeting held on January 09, 2020 approved a proposal to Buy-back up to 57,14,285 (Fifty seven lakhs fourteen thousand two hundred and eighty five only) equity shares of the Company for an aggregate amount not exceeding Rs. 120 crores (Rupees One Hundred and Twenty Crores only) (the "Buyback Size"), being 1.13% of the total paid-up equity share capital, at Rs. 210 (Rupees Two Hundred and Ten only) per equity share (the "Buyback"). The Buyback is proposed to be made from all existing shareholders of the Company as on the record date on a proportionate basis under the tender offer route in accordance with the provisions of the Companies Act, 2013 and the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 (the "Buyback Regulations").

The Buyback Size does not include transaction costs viz. brokerage, applicable taxes such as securities transaction tax, GST, stamp duty, any expenses incurred or to be incurred for the Buyback like filing fees payable to the Securities and Exchange Board of India, advisors/ legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses.

Members of the promoter and promoter group of the Company have indicated their intention to participate in the Buyback.

The Board has determined January 24, 2020 as the record date for the purpose of determining the entitlement and names of the shareholders eligible to participate in the Buyback.





Aster DM Healthcare Limited CIN-L85110KL2008PLC021703

IX/475L, Aster Medcity, Kuttisahib Road Near Kothad Bridge, South Chittoor PO Cheranalloor, Kochi- 682027, Kerala, India Tel: +91 484 6699999, Fax: +91 484 6699862 Email: cs@asterdmhealthcare.com Website: www.asterdmhealthcare.com The public announcement setting out the process, timelines and other requisite details will be released in due course in accordance with the Buyback Regulations. The Company has constituted a Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback.

The Pre-Buyback shareholding pattern as on December 31, 2019 is enclosed as Annexure A.

This is for your information and records.

Thanking you,

For Aster DM Healthcare Limited

Puja Aggarwal

Company Secretary and Compliance Officer

KOCHI-27

ENCL: as above.

Annexure A Pre-Buyback Shareholding Pattern of the Company as on December 31, 2019

Shareholders	No. of shareholders	No. of Shares	% of Shares
Promoter and Promoter Group:			
Individuals	5	2294510	0.45
Companies/Other Entities	1	188706090	37.35
Sub Total	6	191000600	37.80
Indian Financial Institutions*	3	4808113	0.95
Banks	-		
Mutual Funds	6	20167095	3.99
Sub Total	9	24975208	4.94
Foreign Holding:			37
Foreign Institutional Investors/Foreign Portfolio Investors**	27	66082270	13.08
NRIs	1556	28782667	5.70
Foreign Nationals and Overseas Corporate Bodies	4	164812872	32.62
Sub Total	1587	259677809	51.40
Indian Public, Corporates & Others	82857	29573728	5.85
Total	84459	505227345	100.00

Note: All percentages have been rounded off to two decimal points. Thus, the sum of such numbers may not conform exactly to the total figure given.



^{*}Inclusive of Alternate Investment Funds **Inclusive of Foreign Venture Capital Investors